{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 38,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/18",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.56,
        "x": 0.22,
        "y": 0.078
      },
      "kind": "callout",
      "text": "A platinum resensitizing agent is a long-standing desirable and highly demanded mechanism of action of Gvn-Oncs. their so-call “Holy Grail”.*",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79acfecc-3075-4d10-9f0f-e97481ee950a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.29,
        "y": 0.29
      },
      "kind": "diagram",
      "text": "Multi-center, randomized open-label n=186. Experimental Arm: Olvi-Vec + Platinum-doublet + Bevacizumab. Active Comparator Arm: Platinum-doublet + Bevacizumab.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90039ba2-a8bc-42c1-ab5c-3d97c5ab1976",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.26,
        "x": 0.02,
        "y": 0.36
      },
      "kind": "list",
      "text": "High-grade serous, endometrioid, or clear-cell ovarian cancer. Platinum-resistant or -refractory disease. Received prior bevacizumab (or biosimilar) treatment. Received a minimum of 3 prior lines of systemic therapy. ECOG 0 or 1.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92b6e312-cc27-4847-b926-bf7f2010de95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.72,
        "x": 0.14,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64101f49-5217-46c1-80a0-f2c23a62ab0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.26,
        "x": 0.73,
        "y": 0.028
      },
      "kind": "table",
      "text": "Primary Endpoint: Progression-Free Survival. Key Secondary Endpoints: Treatment-emergent AEs, DOR, ORR, OS.",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "518a31c5-8f73-465c-8115-4590aab378d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f813f456-404c-493d-8034-47591ffee360",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "adb3a46b-052b-4ccd-8d22-f7ccf893e231",
      "evidence": "Experimental Arm: Olvi-Vec + Platinum-doublet + Bevacizumab. Active Comparator Arm: Platinum-doublet + Bevacizumab",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "193a681a-4200-418d-b5f9-c1ee46cebe30",
      "evidence": "Standard structure for reporting clinical trial protocols (Inclusion criteria, arms, endpoints)",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 38,
      "from": 10,
      "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}